Please login to the form below

Not currently logged in


This page shows the latest Janssen news and features for those working in and with pharma, biotech and healthcare.

Janssen submits esketamine in Europe for treatment resistant depression

Janssen submits esketamine in Europe for treatment resistant depression

Janssen has filed its new nasal spray-administered treatment for treatment resistant depression with the European Medicines Agency (EMA). ... Janssen (J&J’s pharma division) says this novel mechanism of action could help patients where other treatments

Latest news

More from news
Approximately 128 fully matching, plus 406 partially matching documents found.

Latest Intelligence

  • Chinese biotech’s global ambitions Chinese biotech’s global ambitions

    The firm also has what it hopes is a best- in-class BTK inhibitor, zanubrutinib, in phase III trials, which it believes can be shown superior to Janssen’s Imbruvica.

  • The race for an HIV ‘cure’ The race for an HIV ‘cure’

    Gilead’s HIV work continues apace as does that of rivals GSK, Sanofi, Janssen and others in a global HIV drug market expected to reach a value of $26, 458bn in

  • A quest for innovative solutions A quest for innovative solutions

    Janssen adds: “We spend a lot of time asking how we, as an organisation, can prepare for this future because it is happening right now. ... There are some really exciting projects out there and we are also partnering with academic institutions to use

  • Pharma deals continue to slide Pharma deals continue to slide

    Cerecor has sold its kappa opioid receptor antagonist in phase 2 to Janssen (J&J) and Xoma has licensed its interleukin 1 beta intellectual property for cardiovascular disease to Novartis plus ... 74.5 (upfront 65). Cerecor (US). J&J/Janssen (US). Asset

  • Deal Watch - May 2017 Deal Watch - May 2017

    An example is the deal between Janssen and the Japanese company Peptidream that has a peptide discovery platform. ... Peptidream (CN). Janssen (US). Licence. Peptide discovery platform. Up to 1, 150.

More from intelligence
Approximately 5 fully matching, plus 44 partially matching documents found.

Latest appointments

More from appointments
Approximately 3 fully matching, plus 24 partially matching documents found.

Latest from PMHub

  • Adelphi Research UK wins Agency of the Year at BHBIA Conference

    Adelphi, Janssen and Rethink Mental Illness pro-bono work wins BHBIA Best Conference Paper. ... Adelphi were already excited to work with Janssen and Rethink to generate findings around the Mental Health Act to help lobby government changes, but to have

  • Marketing strategy in complex environments

    Marketing strategy in complex environments. Age-old treatment protocols are being replaced with new and innovative treatment paradigms that will revolutionise the healthcare industry for years to come. Kulveer Singh and Mark Assenti talk through

  • Market Access Transformation

    Pfizer. Janssen. Novartis. Roche. Jazz Pharmaceuticals. Amgen. GSK. Nestle. Gilead. BMS.

  • No Voice, No Choice

    The research was commissioned by Rethink Mental Illness and undertaken by Adelphi Research UK, with support from Janssen Cilag Ltd. ... Rachel Medcalf, Managing Director, Adelphi Research UK commented:. “ It’ s great to be involved in this crucial

  • Patient centricity in the Pharma Industry: why now?

    We interviewed Patient executives from Janssen, Sanofi, AbbVie, Teva, UCB and Novartis.

More from PMHub
Approximately 5 fully matching, plus 32 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...
Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...